Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Interleukin-15 × Clear all
NCT04150562 2022-05-17

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

NCT02395822 2018-02-20

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡